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This review describes the current knowledge regarding genetic susceptibilities and
treatment strategies for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis
(TEN), with ocular complications, in Korea. In a case-control study, the gene frequencies
of both HLA-A∗0206 (20.0%) and HLA-Cw∗0304 (15.0%) increased but the gene
frequency of HLA-Cw∗0303 (1.3%) decreased with cold medicine (CM)-SJS/TEN
with severe ocular complications (SOCs). In a case-series, positive genotyping
of HLA-B∗5801 was 80.0% in allopurinol-induced SJS/TEN without SOCs. In a
genome-wide association study, HLA-A∗0206 was substantially related to CM-SJS/TEN
with SOCs. Both HLA-A∗0206 and prostaglandin-E receptor 3 (PTGER3) single
nucleotide polymorphism (SNP) rs1327464 exert a synergistic effect on SOCs in
CM-SJS/TEN. In the acute stage, conventional procedures, amniotic membrane
transplantation or suture-less amniotic contact lenses are applied. Applications of
intravenous Immunoglobulin (IVIG) or mega-dose steroids are attempted in patients
with high acute ocular and systemic involvement scores. In the chronic stage,
keratolimbal transplantation and penetrating keratoplasty are the standard procedures.
Either autologous nasal or oral mucosal grafts, or biomaterial-free cultured oral
mucosal epithelial cell sheets are transplanted as alternative therapies. Deep anterior
lamellar keratoplasty is attempted. Combined photodynamic therapy with intrastromal
bevacizumab injection or intense pulse laser are used to resolve chronic ocular
complication. Corneoscleral contact lenses are available for a visual rehabilitation. As a
last resort, Seoul-type keratoprosthesis had been transplanted. There are unmet needs
to standardize nationwide ocular grading system and to correct tarsal scarring using
mucosal grafting. This review provides a perspective on the current practices to treat
ocular complications in SJS/TEN.
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INTRODUCTION
Steven-Johnson syndrome (SJS) and its severe form, toxic
epidermal necrolysis (TEN), are severe, inflammatory
vesiculobullous reactions of the skin and mucous membranes.
The mortality rate of SJS and TEN are estimated as 1–10%, and
30%, respectively. According to the Korean National Health
Insurance Database, SJS and TEN are infrequent, yet they
constantly occur throughout the year by showing 3.96 and 0.94
cases per million/year for SJS and TEN, respectively (1). The
management of SJS/TEN imposes a considerable clinical and
financial burden, which is comparable with that of other major
health problems (1, 2). SJS/TEN may permanently damage the
affected mucosa, inducing severe sequelae including the lungs,
genitals and eye. During primary intervention, acute ocular
involvement occurs in approximately 60–100% of SJS/TEN
patients (3–5). In Korea, ocular complications are reported as
the most common complication related to SJS/TEN (1). Patients
with ocular complications spent a considerable amount of money
even after their recovery (2).
It is well known that SJS/TEN can be induced by
various infections or classes of pharmacological agents, such
as antibiotics, anticonvulsants, nonsteroidal anti-inflammatory
drugs (NSAIDS), or allopurinol (6). Among the culprit drugs,
as reported in a nationwide study, anticonvulsants are most
frequent, followed by allopurinol, amoxicillin/dorzolamide,
and acetaminophen (6). Previous pharmacogenomic studies
demonstrated that certain human leukocyte antigen (HLA)
genotypes could induce T-cell activation in response to a specific
drug (7, 8). In a nationwide study that enrolled 5,802 Korean
patients, allele frequencies of HLA-A∗0206, HLA-B∗5801, HLA-
Cw∗0303, and HLA-Cw∗0304 were reported to be 10.3, 7.0,
10.9, and 9.1%, respectively (9). Specific genetic risk factors play
an important role in the development of SJS/TEN. Recently, a
genome-wide association study (GWAS) with a single nucleotide
polymorphism (SNP) microarray has been employed to detect an
association between SNPs and SJS/TEN (10, 11).
This review describes the current knowledge on the clinical
aspect and treatment strategies for SJS/TEN, with ocular
complications, in Korea. We summarized the HLA genotypes
and the associated drugs for Koreans responsible for severe
ocular complications (SOCs) in the acute and chronic stage of
SJS/TEN, and elaborated upon the treatment strategies.
OVERVIEW OF CAUSATIVE DRUGS AND
GENETIC PREDISPOSITION IN KOREAN
PATIENTS WITH SJS/TEN WITH SOCs
Regarding frequencies of the culprit medications related with
SOCs in Korea, cold medicine is the highest frequency, but
antibiotics, allopurinol, or anti-epileptic drugs are not related to
SOCs (12).
Allopurinol
Allopurinol, a xanthine oxidase inhibitor, has been widely used
to manage hyperuricemia and gout. Several studies report a
strong association of the HLA-B∗5801 genotype and allopurinol-
induced SJS/TEN among Koreans (7–13%) (13–15). A recent
study revealed that HLA-B75, DR13 homozygosity, or DR-
14 increased the risk of allopurinol-induced SJS/TEN when
combined withHLA-B∗5801, especially in patients with impaired
renal function (14, 16). Compared to other drugs, allopurinol-
induced SJS/TEN was associated with longer and more severe
systemic manifestations, resulting in a high mortality rate (15);
however, allopurinol-induced SJS/TEN may not cause serious
acute or chronic ocular surface complications (12, 17). In a
case-series, HLA-B∗5801 genotype was observed in 80.0% of
allopurinol-induced SJS/TEN without SOCs (17).
Anti-epileptic Drugs
In a nationwide registry-based study, themost common causative
AEDs were carbamazepine, lamotrigine, and levetiracetam (18,
19). In the case of AEDs-induced SJS/TEN, aromatic AEDs
(e.g., carbamazepine, lamotrigine) were greatly associated with
a severe reaction than non-aromatic AEDs (e.g., valproic acids)
(19). It may be caused that AEDs containing an aromatic
ring can form an arene-oxide intermediate, resulting in a
hypersensitivity reaction (19). HLA-B∗1502, which is closely
related to SJS/TEN, is very rare in Koreans (7, 20). Several HLA
genes are weakly associated with AEDs-induced hypersensitivity
syndrome in the Korean population, but not with SJS/TEN (7,
20). Ocular manifestations are relatively mild in AEDs-induced
SJS/TEN (12).
Cold Medicine
Cold medicine (CM), including NSAIDS and acetaminophen,
is relatively safe; however, it can trigger SJS/TEN in patients
with suspected viral infection mediated by T-cells and monocytes
(12, 21). SJS/TEN with severe ocular complications (SOCs) are
commonly associated with CM in the Korean population (10,
22–25). In GWAS, HLA-A∗0206 was considerably related to
CM-SJS/TEN with SOCs (22). In addition, both HLA-A∗0206
and prostaglandin-E receptor 3 (PTGER3) single nucleotide
polymorphism (SNP) rs1327464 exert synergistic effect in CM-
SJS/TENwith SOCs (23). A recent multicenter case-control study
suggested that HLA-Cw∗0304 may also be a positive marker
for CM-SJS/TEN with SOCs; however, HLA-Cw∗0303 may be
an indicator of protection against this disease in the Korean
population (24). In a worldwide GWAS that enrolled Korean,
Japanese, Indian, and Brazilian patients, IKAROS family zinc-
finger 1 (IKZF1) was revealed as a novel susceptibility gene
(meta-analysis, rs4917047) for CM-SJS/TEN with severe mucosal
involvement (25).
Carbonic Anhydrase Inhibitors
Surprisingly, both topical and oral formulations of CAIs, such
as acetazolamide, methazolamide, and dorzolamide, can induce
SJS/TEN (6, 26). HLA-B∗5901 genotype, which occurs in 2.1% of
the Korean population, has been suggested as a genetic marker
for CAIs-induced SJS/TEN (27, 28). CAIs-induced SJS/TEN
results in more extensive cutaneous manifestations and frequent
ocular sequelae when compared with SJS/TEN due to other
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drugs including allopurinol, anticonvulsants, or anti-tuberculosis
drugs (29).
Other Drugs
Antibiotics such as amoxicillin/clavulanate and cephalosporin
are the most common causative drugs in pediatric patients with
SJS/TEN (30). However, there is no report stating that antibiotics
may be related to SOCs (12). The anti-human immunodeficiency
virus agents including abacavir and nevirapine could induce
a hypersensitive reaction associated with HLA-B∗5701 (7).
However, HLA-B∗5701 is not a clinically critical allele, since it
is rare in Koreans (31).
TREATMENT STRATEGY IN KOREAN
PATIENTS WITH SJS/TEN WITH SOCs IN
THE ACUTE STAGE
General supportive care with anti-inflammatory intervention is
the mainstay to restore barrier function of the skin and mucous
membrane, and fluid balance, and to treat the infection (3, 10).
The Korean severe cutaneous adverse drug reactions (SCARs)
registry includes patients who were diagnosed with SJS and
TEN (18, 32). Ocular involvement was in the ranges of 34–
43% in Korea (1, 30). Therefore, therapeutic approaches to
SJS/TEN should be multidisciplinary (3, 10). In Korea, patients
with SJS/TEN are usually referred to the ophthalmologists
upon presenting with complaints of ocular symptoms during
hospitalization. Given that there is window of time within
which vision-saving treatments can be applied, ophthalmologic
consultation upon admission or within 24–48 h after diagnosis
is critical (3, 10). The concept of a multidisciplinary approach,
including eye care, should be shared with a primary physician.
There are local and systemic interventions to treat ocular
complications in the acute stage of SJS/TEN (3, 10, 33, 34). As
local treatments, aggressive lubrication, mechanical membrane
removal/synechiolysis, bandage contact lens (CL) placement,
and topical antibiotics and steroid application are implemented
(3). Preservative-free artificial tears are instilled every 1–2 h
and eyedrops containing hyaluronate are preferred in epithelial
defected ocular surface. All membranes should be mechanically
removed (33). However, there is no consensus about how
often either membrane removal or synechiolysis be conducted
since cotton-tip application can induce mechanical trauma.
The benefits of mechanical synechiolysis should be cautiously
weighed against the intervention-induced inflammation. One
percentage topical prednisolone acetate combined with antiseptic
eyedrops containing fluoroquinolone are preferably applied.
0.5–1.5% levofloxacin or 0.5% moxifloxacin eyedrops are
administered three to four times a day. Topical 1% prednisolone
acetate is administered every 2–3 h depending on the severity.
High-oxygen-transmissible silicone hydrogel CL with medium
water content (35–46%) such as Acuvue Oasys, Acuvue
Advance, and PureVision are available to cover corneal epithelial
defects (35).
Although there is no worldwide consensus on a grading
system to assess severity of acute ocular involvement in
SJS/TEN, new grading systems are currently being proposed
(34, 36, 37). Sotozono et al. proposed a grading scale of 0–
3 using three parameters, including conjunctival hyperemia,
ocular surface epithelial defect, and pseudomembrane (36).
Gregory et al. proposed four grading scales based on the
presence of epithelial defected area with three parameters,
including conjunctiva, cornea, and lid margin (37). In French,
they reached a nationwide consensus on a diagnostic grading
system for acute ocular complications that consists of three
stages of severity using seven parameters (34). In Korea, we
have not reached a consensus yet on grading system for
acute ocular complications. The authors working with the
international collaboration network of ocular SJS/TEN led
by Kinoshita currently use the grading scales proposed by
Sotozono (17, 38). Therefore, a nationwide consensus on the
grading system to evaluate acute ocular complications should
be established.
Amniotic membrane transplantation (AMT) is a standardized
procedure for the severe acute ocular complication. AMT within
the first 7–10 days can potentially avoid vision-threatening
chronic complications (33, 37, 39). The indication of AMT
includes (1) any corneal epithelial defect, (2) staining of the eyelid
margin> 1/3 of its length, or (3) any conjunctival staining>1 cm
at its greatest diameter and/or (4) pseudomembrane formation
(33, 37, 39). There are two studies reporting the effect of AMT
on visual improvement or SOCs in SJS/TEN in Korea (38, 40).
One of the reports had presented the beneficial effect of AMT
on visual improvement and SOCs (40). On the contrary, the
other report showed that AMT was related with a poor final
visual outcome; however, it did not mention when the AM
was transplanted (38). AMT in the latter study may not be a
timely treatment. The AMT technique to cover the whole ocular
surface including fornix and the eyelid was recently standardized
using the symblepharon ring and lid bolsters (39, 41, 42). In
Korea, a similar technique of AMT was adapted. For a bedside
application, ProKera is available in western countries (43),
whereas suture-less amniotic membrane patch with a silicone
ring (44) or suture-less amniotic CL is available in Korea. Effect
of amniotic CL on wound healing was comparable to that of
AMT in vivo study (Figure 1A, Supplementary Video 1) (45).
However, the size of the amniotic CL is just enough to cover
the cornea.
Systemic anti-inflammatory treatment is of utmost
importance in reducing inflammation for both the body and the
eye. So far, the effect of systemic intravenous immunoglobulin
(IVIG) or mega-dose steroids on SOCs has been the subject of
debate (38). In Korea, IVIG or mega-dose steroids are sometimes
used for treatment of patients with high acute ocular and systemic
involvement (38). A recent SCAR registry-based study showed
that most of the patients have been treated with systemic steroid
with an average maximal dose of 60 mg/day (18). Additionally,
87.5, 0.6, and 11.8% of the patients were treated using systemic
steroids, IVIG, and both systemic steroids and IVIG, respectively
(18); whereas, 49, 17, and 28% of the pediatric patients received
systemic steroids, IVIG, and both systemic steroids and IVIG,
respectively (30). It revealed that pediatric patients were more
treated with IVIG compared to adults (18, 30). Considering
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FIGURE 1 | Various non-surgical and surgical modalities to treat ocular complications in Stevens-Johnson syndrome or Toxic epidermal necrosis are introduced. (A)
Commercially available suture-less amniotic contact lens. (B) Photodynamic therapy with verteporfin combined with intrastromal bevacizumab injection. (C)
Seoul-type keratoprosthesis. (D) Autologous nasal mucosal grafting (yellow-highlighted) combined with penetrating keratoplasty and keratolimbal allografting. A thick
mucus is often secreted by the nasal mucosal graft (red arrow).* (E) Circumferential autologous oral labial mucosal grafting. (F) Biomaterial-free cultured oral mucosal
epithelial cell sheets (COMECs) transplantation (yellow arrows) with H&E and K13 immunofluorescent staining. (G) Intense pulsed light. (H) Corneoscleral contact lens.
that children with SJS/TEN have higher ocular and systemic
complications than adults do (46, 47), such a treatment
pattern may be reasonable. Combined treatment of IVIG and
systemic steroids may be beneficial to reduce both SOCs and
systemic complications.
TREATMENT STRATEGY IN KOREAN
PATIENTS WITH SJS/TEN WITH SOCS IN
THE CHRONIC STAGE
Complex ocular sequelae, such as symblepharon, lid
malformation, trichiasis, conjunctival keratinization, limbal
stem cell deficiency, corneal pannus, and dry eye occur in
the chronic stage in patients with SJS/TEN. The goal of
treatment in the chronic stage is the preservation of visual
function, and reduction of the inflammation and persistent
discomfort. Herein, surgical and medical interventions that have
been currently practiced in Korea are presented (Table 1 and
Figure 1).
Medical Intervention Strategies
Chronic inflammation has been controlled by various medical
interventions, such as serum eyedrops, topical or systemic
steroid, and immunosuppressants. Autologous serum eye
drops contain many anti-inflammatory molecules and are
effective in reducing inflammation on the ocular surface
(54); however, the components of serum eye drops may
differ depending on the general condition of the patient.
Steroid is effective but has undesirable adverse effects
including glaucoma, cataract, infection, and delayed wound
healing (55). Topical 0.02% tacrolimus ointment, originally
approved for dermatologic purpose, is a good alternative to
topical steroid (56). Topical 0.02% tacrolimus ointment was
added to treat refractory chronic conjunctival inflammation
in six SJS patients with tapering of the topical steroid
(56). Topical tacrolimus decreased surface inflammation,
corneal neovascularization, and intraocular pressure within
4 weeks (56).
Additionally, infection of the ocular surface should be closely
monitored especially in SJS/TEN with SOCs. Unlike healthy
people who show a high diversity of ocular microbiomes with
prevalent streptococcus and lactobacillus, staphylococcus is a
predominant bacteria with a less diversity with SJS, which can
become easily pathogenic (57). A report in Korea presented
higher rate of infective keratitis (35%) in LSCD with SJS than
in those with a chemical burn (18%) (58). The higher the score
of chronic ocular complications is, the more frequently infective
keratitis develops in SJS (58).
Besides, tear film is unstable and meibomian gland is
dysfunctional by the sequelae of SJS, and the degrees of
meibomian gland disease tend to be correlated with the severity
of SJS (59). Intense pulsed light is used to improve meibum
expressibility (Figure 1G) (60). It contributes to decreased
inflammatory cytokines such as IL-4,−6,−10, 17A, and TNF-α.
IPL can be applied to stabilize tear film and reduce inflammatory
cytokines, thereby treating severe meibomian gland obstruction
in SJS.
Finally, corneoscleral CL with a total diameter of 14.0mm
is available for non-surgical visual rehabilitation in Korea (61).
Fitting of a corneoscleral CL improved the vision by reducing
corneal punctate erosions and reconstructing a new optical
surface in six of eight SJS patients (Figure 1H) (61).
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Han E. S. (48) 6 LSCD (± symblepharon) KLAL (±PKP/AMT) 33.3 66.7 49.5
Choi S. E. (47) 3‡ LSCD KLAL + PKP 33.3 NA NA
Wee S. W. (49) 2 Failed previous PKP +
corneal ulcer/opacification**
DALK + AMT (±additional
PKP)
100 100 15
Kim M. K. (50) 6 Total LSCD + corneal
opacity/symblepharon
S-KPro implantation 100 100†† 46.8ζ
















AMT, Amniotic membrane transplantation; COMECs, Biomaterial-free cultured oral mucosal epithelial cell sheets; DALK, Deep anterior lamellar keratoplasty; FU, follow-up; KLAL,
Keratolimbal allograft; LSCD, Limbal stem cell deficiency; Ms, Months; N, Number; NA, not available data; PKP, penetrating keratoplasty; SJS, Stevens-Johnson syndrome; S-KPro,
Seoul-type keratoprosthesis; TEN, Toxic epidermal necrolysis.
*Success; Success has been defined as the cornea has been well maintained without persistent epithelial defect at least 6 months after the surgery.
†Visual improvement has been defined as at least one-line increase of post-operative best corrected visual acuity during the follow-up compared with pre-operative best corrected
visual acuity.
‡Children SJS/TEN.
**This study did not mention whether LSCD was present or not.
††The visual improvement has been assessed only in 3 SJS patients after exclusion of the other three patients who had a previous amblyopia, glaucoma, or retinal detachment.
ζPrimary retention time of S-KPro.
The Outcome of Surgical Interventions
Intense immunologic reactions destruct limbal stem cells.
Subsequently, corneal pannus occurs due to the loss of the
limbal barrier function. Despite a high risk of rejection,
keratolimbal allograft (KLAL) and penetrating keratoplasty
(PKP) are standard procedures for visual rehabilitation. The
clinical outcomes of various surgical interventions to treat
chronic limbal stem cell deficiency (LSCD) in Korean SJS/TEN
patients are shown in Table 1.
Eyes with SJS demonstrated a 33.3% of short-term success
rate (≥6 months) and 16.7% of long-term success rate (≥2
years) in KLAL, which showed the least success rate among
patients with LSCD (48). In children with SJS/TEN, LSCD
developed in 32%, and combined PKP with KLAL failed in
two (67%) out of three children (47). Deep anterior lamellar
keratoplasty was attempted using acellular cornea with AMT
in two eyes with previous failed PKP (49). One of them
kept the cornea clear with epithelization. The other eye
which needed additional PKP showed no additional corneal
opacity (49). Photodynamic therapy with verteporfin combined
with intrastromal bevacizumab injection was also applied to
reduce corneal neovascularization (Figure 1B) (62). Within 6
months, five of eight eyes showed complete regression and the
remaining eyes showed partial regression (62). In a few cases,
Seoul-type keratoprosthesis (S-KPro) had been transplanted
(Figure 1C) (50, 63). In the six S-KPro-implanted eyes of SJS,
mean retention and visual preservation time was 46.8 and
35 months, respectively. To correct conjunctival keratinization
with symblepharon or a LSCD, mucosal grafting has been
attempted. A report presented successful reconstruction of the
ocular surface and visual improvement by autologous nasal
mucosal grafting accompanied with PKP and KLAL in a patient
with SJS (Figure 1D) (51). Another report revealed visual
improvement with a stable ocular surface by circumferential
autologous oral labial mucosal grafting at the limbus in all four
SJS patients (Figure 1E) (52). Recently, biomaterial-free cultured
oral mucosal epithelial cell sheets (COMECs) transplantation has
proven some efficacy on an LSCD in a clinical trial (Figure 1F)
(53). Although the initial migration of the oral mucosal epithelial
cells harvested from SJS patients (SJS-cells) was delayed with
lower levels of epidermal growth factor and higher levels of
vascular endothelial growth factor, compared to those of non-
SJS cells, in vivo transplanted SJS-COMECs revealed similar
expression of cytokeratin and stem cell markers as in non-
SJS COMECs (64, 65). COMECs were transplanted in six SJS
patients, and five eyes achieved complete reepithelization in a
mean follow-up of 10.2 months (53). Among those five eyes,
visual acuity was improved in four eyes with/without PKP (53).
Although the outcomes of various surgical interventions
to treat LSCD cannot be directly compared due to different
indications and follow-up periods (Table 1), autologous nasal or
oral mucosal grafting, COMEC transplantation seem to show
better successful outcome with visual improvement compared
with that in KLAL. Meanwhile, first S-KPro implantation showed
long-term successful outcome with visual improvement (50).
However, due to skirt exposure, secondary exchange of S-KPro
was mandatory in all S-KPro implanted patients (50). Given
that retinal detachment developed in all S-KPro-exchanged eyes
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within 2 months (50), S-KPro implantation can be considered
as a last resort. In Korea, less attention is paid to correction
of scarring of the tarsal conjunctiva and lid malformation
in SJS patients. There have been no reports regarding the
reconstruction of tarsal scarring using a mucosal grafting in
SJS yet.
DISCUSSION
In Korea, about 40% of the SJS/TEN patients suffer from
chronic ocular complications. HLA-A∗0206 combined with
PTGER3 SNP rs1327464 enhances genetic susceptibility in
CM-SJS/TEN with SOCs, whereas HLA-C∗03:03 may be an
indicator of protection against CM-SJS/TEN with SOCs. For the
timely treatment of acute ocular complications, a nationwide
consensus on ocular grading system should be reached, and a
multidisciplinary approach including ophthalmologists should
be standardized in Korea. In the chronic stage, various innovative
surgical and medical modalities have been attempted to restore
vision and stable ocular surface. Notably, both oral and nasal
mucosal grafting as well as COMECs transplantation hold the
most promise in the treatment of LSCD of Korean patients
with SJS/TEN at present. However, the enrolled patient numbers
were too small and the follow-up was too short to verify the
long-term clinical efficacy. Therefore, large scale study with
long-term follow-up should be further conducted. This review
provides insightful information about genetic predisposition and
current strategies to treat ocular complications of SJS/TEN in
Korean population and gives us a perspective on how to improve
current practice.
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